Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Goodwill & Intangibles (2021 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Goodwill & Intangibles for 5 consecutive years, with $88.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Goodwill & Intangibles fell 27.67% year-over-year to $88.1 million, compared with a TTM value of $88.1 million through Dec 2025, down 27.67%, and an annual FY2025 reading of $88.1 million, down 27.67% over the prior year.
  • Goodwill & Intangibles was $88.1 million for Q4 2025 at Xeris Biopharma Holdings, down from $93.5 million in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $143.5 million in Q4 2022 and bottomed at $22.9 million in Q1 2022.
  • Average Goodwill & Intangibles over 5 years is $94.3 million, with a median of $108.4 million recorded in 2023.
  • The sharpest move saw Goodwill & Intangibles soared 403.9% in 2023, then fell 27.67% in 2025.
  • Year by year, Goodwill & Intangibles stood at $131.4 million in 2021, then rose by 9.14% to $143.5 million in 2022, then dropped by 7.56% to $132.6 million in 2023, then dropped by 8.18% to $121.8 million in 2024, then decreased by 27.67% to $88.1 million in 2025.
  • Business Quant data shows Goodwill & Intangibles for XERS at $88.1 million in Q4 2025, $93.5 million in Q2 2025, and $121.8 million in Q4 2024.